Clinical trial · no report yet · Phase 2

NCT05891080

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

NCT05891080 ↗
Not yet recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	3

The trial

ClinicalTrials.gov

Official title: Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
Phase: Phase 2
Status: Not yet recruiting
Conditions: Stage III Non-small Cell Lung Cancer
Interventions: Toripalimab; JS004; Pemetrexed; Nab-paclitaxel; Carboplatin; Surgery
Arms: Safety run-in arm · Experimental
JS004 arm · Experimental
Control arm · Active comparator
Enrollment: 124 (estimated)
Primary outcomes: Pathologic complete response (PCR) rate
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Start: Jul 1, 2023 (estimated)
Primary completion: Jul 1, 2025 (estimated)
Results posted: No
Registry record: NCT05891080 · updated Jun 6, 2023